Journal
NEUROTHERAPEUTICS
Volume 19, Issue 6, Pages 1782-1798Publisher
SPRINGER
DOI: 10.1007/s13311-022-01261-4
Keywords
Leptomeningeal metastases; Leptomeningeal disease; Central nervous system metastases; Brain metastases; Cerebrospinal fluid; Intrathecal therapy; Craniospinal radiation
Ask authors/readers for more resources
Leptomeningeal metastases, which can cause significant neurological damage and death, remains a challenging disease to treat. However, there is hope as several studies and clinical trials have shown that certain cancer-directed strategies are effective in improving survival rates for patients with this condition. Further clinical trials are needed to establish the efficacy of treatments and to explore new avenues of treatment.
Leptomeningeal metastases arise from cancer cell entry into the subarachnoid space, inflicting significant neurologic morbidity and mortality across a wide range of malignancies. The modern era of cancer therapeutics has seen an explosion of molecular-targeting agents and immune-mediated strategies for patients with breast, lung, and melanoma malignancies, with meaningful extracranial disease control and improvement in patient survival. However, the clinical efficacy of these agents in those with leptomeningeal metastases remains understudied, due to the relative rarity of this patient population, the investigational challenges associated with studying this dynamic disease state, and brisk disease pace. Nevertheless, retrospective studies, post hoc analyses, and small prospective trials in the last two decades provide a glimmer of hope for patients with leptomeningeal metastases, suggesting that several cancer-directed strategies are not only active in the intrathecal space but also improve survival against historical odds. The continued development of clinical trials devoted to patients with leptomeningeal metastases is critical to establish robust efficacy outcomes in this patient population, define drug pharmacokinetics in the intrathecal space, and uncover new avenues for treatment in the face of leptomeningeal therapeutic resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available